🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-524690-16-00
Ongoing Phase I

Open-label study of BBO-11818 in adult subjects with KRAS mutant cancer

2025-524690-16-00 · tracked via the Priya Life Science EU tracker
Sponsor
Theras Inc.
Sponsor type
Pharmaceutical company
Therapeutic area
Neoplasms
Decision date
16/06/2026
Enrollment target
2999997
Sites
Spain, Italy, France

Condition studied

Solid Tumors

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524690-16-00 on CTIS ↗ ← All trials in the EU